ストックスクリーナーアプリを入手
17.60
8.57%
-1.65
前日終値:
$19.25
開ける：
$19.28
24時間の取引高:
236.23K
Relative Volume:
1.30
時価総額：
$1.18B
収益：
$-9,000
当期純損益:
$-68.03M
株価収益率:
-16.76
EPS:
-1.05
ネットキャッシュフロー:
$-44.76M
1週間 パフォーマンス:
-8.76%
1か月 パフォーマンス:
+19.16%
6か月 パフォーマンス:
+13.11%
1年 パフォーマンス:
+12.82%
1日の値動き範囲:
$17.45
$19.35
1週間の範囲:
$17.45
$20.20
52週間の値動き範囲:
$13.77
$25.00
Pulse Biosciences Inc Stock (PLSE) Company Profile
PLSE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
17.60 | 1.30B | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
429.59 | 159.08B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
186.56 | 54.20B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
272.00 | 40.55B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
72.05 | 36.85B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
261.77 | 18.95B | 2.96B | 487.70M | 344.00M | 6.6758 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-07 | 開始されました | Oppenheimer | Outperform |
| 2021-07-27 | 開始されました | Stephens | Overweight |
| 2021-03-11 | 開始されました | Maxim Group | Buy |
| 2021-01-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-12 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Pulse Biosciences Inc (PLSE) 最新ニュース
Pulse Biosciences Reveals Positive First-in-Human PFA Data - Medical Product Outsourcing
Is Pulse Biosciences Inc. stock bottoming outJuly 2025 Institutional & Low Risk Entry Point Tips - newser.com
Pulse Biosciences announces presentation of late-breaking data from the nPulse cardiac surgical system - MarketScreener
Pulse Biosciences Announces Results from nPulse Cardiac Surgical System Study - TradingView
Pulse Biosciences, Inc. Announces Presentation of Late-Breaking Data from the nPulse Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - MarketScreener
Pulse Biosciences reports positive results for cardiac ablation system - Investing.com India
Pulse Biosciences reports positive results for cardiac ablation system By Investing.com - Investing.com South Africa
Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Yahoo Finance
Is now a turning point for Pulse Biosciences Inc.July 2025 Intraday Action & AI Enhanced Market Trend Forecasts - newser.com
Pulse Biosciences (NASDAQ:PLSE) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Heatmap analysis for Pulse Biosciences Inc. and competitorsJuly 2025 Trends & Long-Term Capital Growth Strategies - newser.com
Will Pulse Biosciences Inc. continue its uptrendMarket Activity Summary & Real-Time Sentiment Analysis - newser.com
What analysts say about Pulse Biosciences Inc 6L8 stockTrendline Breakouts & Outstanding Investment Portfolio - earlytimes.in
Insider Selling: Pulse Biosciences (NASDAQ:PLSE) Insider Sells 4,600 Shares of Stock - MarketBeat
Pulse Biosciences introduces nPulse Vybrance for nsPFA technology - Traders Union
Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - Investing News Network
Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting - MarketScreener
Pulse Biosciences (NASDAQ:PLSE) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Pulse Biosciences (PLSE) Is Up 11.1% After FDA Clears Cardiac Ablation StudyWhat's Changed - Sahm
Pulse Biosciences (PLSE): Evaluating Its Valuation After Recent Investor Interest - Sahm
Using Ichimoku Cloud for Pulse Biosciences Inc. technicals2025 Dividend Review & Technical Buy Zone Confirmation - newser.com
What does recent volatility data suggest for Pulse Biosciences Inc.Buy Signal & Momentum Based Trading Signals - newser.com
Pulse Biosciences Expands Equity Incentive Plan - MSN
Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial - Insider Monkey
What drives Pulse Biosciences Inc 6L8 stock priceStock Buy Signals & Invest Now – Opportunity Window Closing - earlytimes.in
Will Pulse Biosciences Inc. stock beat EPS estimatesTrade Exit Summary & Low Risk High Win Rate Picks - newser.com
First Procedures Conducted in PRECISE Benign Thyroid Nodule Study - Medical Product Outsourcing
Pulse Biosciences (NASDAQ:PLSE) Shares Up 6.3%Should You Buy? - MarketBeat
Pulse Biosciences (PLSE) Is Up 6.4% After FDA Clears nsPFA Device for Thyroid Treatment - Sahm
17,800 Shares in Pulse Biosciences, Inc $PLSE Purchased by Strs Ohio - Defense World
Pulse Biosciences, Inc. (PLSE) Stock Analysis: Exploring a 25% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Pulse Biosciences (NASDAQ:PLSE) Shares Up 9.8%Still a Buy? - MarketBeat
Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock - MarketBeat
Pulse Biosciences CCO Danahy sells $377k in shares By Investing.com - Investing.com Canada
Pulse Biosciences (NASDAQ:PLSE) CTO Darrin Uecker Sells 20,000 Shares - MarketBeat
Pulse Biosciences Inc (PLSE) 財務データ
収益
当期純利益
現金流量
EPS
Pulse Biosciences Inc (PLSE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
1.03%
大文字化:
|
ボリューム (24 時間):